Literature DB >> 9732134

Classification of patients with Ménière's disease using otoacoustic emissions.

W M van Huffelen1, N J Mateijsen, H P Wit.   

Abstract

Otoacoustic emissions (OAEs) were studied in patients with Ménière's disease in order to assess their usefulness for distinguishing between different stages of the disease. An accurate classification of Ménière's patients is expected to allow optimalization of the treatment for each particular stage. Click-evoked and distortion product OAEs were evaluated in both ears for 70 Ménière's patients. Based on these measurements, Ménière's patients can be divided into four different categories. In patients with small hearing losses OAEs are found, whereas patients with pure-tone thresholds larger than 60 dB exhibit no OAEs at all. In the intermediate range (30- to 60-dB thresholds) two categories of patients are distinguished: patients with relatively large emissions and patients without measurable emissions. These findings suggest the presence of various stages in the pathophysiological mechanism involved in Ménière's disease. Additionally, Ménière's patients with contralateral ears with normal thresholds have significantly smaller emissions than normal-hearing adults. This observation could represent a very early manifestation of bilateral Ménière's disease, which cannot be detected by other diagnostic methods.

Entities:  

Mesh:

Year:  1998        PMID: 9732134     DOI: 10.1159/000013810

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  2 in total

1.  Role of transient evoked otoacoustic emission beyond screening of hearing impairment: a study of 400 cases.

Authors:  Rakesh Singh Meena; Deepali Meena; Dinesh Babu; B K Singh; P C Verma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-12-13

Review 2.  Assessment Tools for Use in Patients with Ménière Disease: An Update.

Authors:  Andrea Ciorba; Piotr Henryk Skarżyński; Virginia Corazzi; Chiara Bianchini; Claudia Aimoni; Stavros Hatzopoulos
Journal:  Med Sci Monit       Date:  2017-12-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.